Govt spent Rs 19,675 cr spent on coronavirus vaccine procurement: Data

The Centre has spent Rs 19,675 crore to procure Covid-19 vaccines for free of cost supply to states and Union territories, according to government data.

Vaccination
Healthcare workers inoculate beneficiaries against Covid-19 during a vaccination camp at Shahaji Raje Sport Complex, at Andheri West in Mumbai (Photo: PTI)
Press Trust of India New Delhi
2 min read Last Updated : Dec 23 2021 | 7:03 PM IST

The Centre has spent Rs 19,675 crore to procure COVID-19 vaccines for free of cost supply to states and Union territories, according to government data.

The government had earmarked Rs 35,000 crore in the Union Budget 2021-2022 for COVID-19 vaccination.

"It is informed that an expenditure of Rs 19,675.46 crore has been incurred for procurement of COVID-19 vaccines for free of cost supplies to states and Union territories by December 20," read a reply to an RTI application filed by social activist Amit Gupta.

The Union health ministry's COVID-19 Vaccine Administration Cell said that 117.56 crore i.e. 96.5 per cent doses have been administered at government Covid Vaccination Centres (CVCs) from May 1 to December 20.

"About 4.18 crore doses have been administered at private CVCs, which include 3.55 crore doses of Covishield, 0.51 crore doses of Covaxin and 0.ll crore doses of Sputnik V vaccine," it said.

Under the 'Revised Guidelines for Implementation of National COVID Vaccination Program' effective from June 21, domestic vaccine manufacturers have the option to provide up to 25 per cent of their monthly vaccine production directly to private hospitals and any leftover vaccine is also procured by the government of India.

According to the CoWIN portal, over 140 crore doses have been administered in the country since the inoculation exercise started on January 16. As many as 56.79 crore people have received both the doses.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Dec 23 2021 | 7:03 PM IST

Next Story